The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of parkinson’s disease

Experimental Neurology

Volumn 166, Issue 2, 2000, Pages 235-245

  Moussaoui, Saliha ^a   Obinu, Maria Carmen ^a   Daniel, Nadine ^a   Reibaud, Michel ^a   Blanchard, Véronique ^a   Imperato, Assunta ^a  

^a SANOFI   (France)

Author keywords

1 methyl 4 phenyl 1, 2, 3, 6 tetrahydropyridine; Antioxidant; Ebselen; Free radicals; Glutathione peroxidase mimicking; Marmoset; Mitochondrial dysfunction; Neuroprotection; Parkinson's disease

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANTIOXIDANT; DOPAMINE; EBSELEN; FREE RADICAL; GLUTATHIONE PEROXIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN MITOCHONDRION; BRAIN PROTECTION; CELL LOSS; CONTROLLED STUDY; DRUG MECHANISM; MALE; NERVE CELL NECROSIS; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; STROKE; SYMPTOMATOLOGY;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; ANTIOXIDANTS; AZOLES; BEHAVIOR, ANIMAL; BLOOD PROTEINS; CALLITHRIX; CAUDATE NUCLEUS; DISEASE MODELS, ANIMAL; FEMALE; FREE RADICALS; GLUTATHIONE PEROXIDASE; HERBICIDES; LOCOMOTION; MALE; MITOCHONDRIA; MOLECULAR MIMICRY; NEURONS; NEUROPROTECTIVE AGENTS; ORGANOSELENIUM COMPOUNDS; PARKINSONIAN DISORDERS; PC12 CELLS; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA; TRITIUM;

EID: 0033669158     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.2000.7516     Document Type: Article

References (36)

1. + induced oxygen radical formation with mitochondrial enzymes
2. Neurodegenerative disorders in humans: The role of glutathione in oxidative stress-mediated neuronal death
3. Chronic exposure to MPTP as a primate model of progressive parkinsonism: A pilot study with free radical scavenger
4. A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by 1-methyl-4-phenyl-1, 2, 2, 6-tetrahydropyridine
5. +
6. Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: Evidence for free radical involvement
7. Chronic parkinsonism secondary to intravenous injection of meperidine analogues
8. +) cytotoxicity
9. Effect of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) on levels of glutathione in the extrapyramidal system of the mouse
10. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor
11. Inhibitory effects of Ebselen on lipid peroxidation in rat liver microsomes
12. Repeated stressful experiences differently affect limbic dopamine release during and following stress
13. Understanding cell death in Parkinson's disease
14. +)-related compounds in rat pheochromocytoma PC12 cells
15. Dilemma in the treatment of Parkinson's disease with L-dopa
16. Chronic parkinsonism in humans due to a product meperidineanalog synthesis
17. Improved method for the estimation of hydroxyl free radical levels in vivo based on liquid chromatography with electrochemical detection
18. Inhibition of complex I by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)
19. Treatment with antioxidants does not prevent loss of dopamine in the striatum of MPTP-treated common marmosets: Preliminary observations
20. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
21. Immunohistochemical analysis of presenilin-1 expression in the mouse brain
22. A novel biologically active seleno-organic compound. I. Glutathione peroxidase-like activity in vitro and antioxidant capacity of PZ51 (Ebselen)
23. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease
24. Intraventricular infusion of basic fibroblast growth factor (bFGF) in the MPTP-treated common marmoset
25. Parkinson's disease: A disorder due to nigral glutathione deficiency
26. Transition metals: Ferritin glutathione and ascorbic acid in Parkinsonian brains
27. Neuroprotective effect of an antioxidant Ebselen in patients with delayed neurological deficits after aneurysmal subarachnoid hemorrhage
28. Mitochondrial complex I deficiency in Parkinson's disease
29. Striatal dopamine deficiency in Parkinson's disease: Role of aging
30. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative diseases affecting basal ganglia
31. Evidence for generation of oxidative stress in brain by MPTP: In vitro and in vivo studies in mice
32. A novel biologically active seleno-organic compound. II. Activity of PZ51 in relation to glutathione peroxidase
33. + toxicity in nigral dopaminergic neurones
34. Ebselen in acute ischemic stroke: A placebo-controlled double-blind clinical trial
35. Depletion of glutathione in brainstem of mice caused by N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine is prevented by antioxidant pretreatment